Literature DB >> 22095436

Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense.

Zora Teltschik1, Reiner Wiest, Julia Beisner, Sabine Nuding, Claudia Hofmann, Juergen Schoelmerich, Charles L Bevins, Eduard F Stange, Jan Wehkamp.   

Abstract

UNLABELLED: Liver cirrhosis is associated with bacterial translocation (BT) and endotoxemia. Most translocating bacteria belong to the common intestinal microbiota, suggesting a breakdown of intestinal barrier function. We hypothesized that diminished mucosal antimicrobial host defense could predispose to BT. Two rodent models of portal hypertension with increased BT were used, CCl(4)-induced ascitic cirrhosis and 2-day portal vein-ligated (PVL) animals. BT was assessed by standard microbiological techniques on mesenteric lymph nodes. Total RNA was isolated systematically throughout the intestinal tract, and expression of Paneth cell α-cryptdins and β-defensins was determined by real-time quantitative polymerase chain reaction (qPCR). To determine functional consequences, mucosal antimicrobial activity was assessed with a fluorescence-activated cell sorting assay. BT was detectable in 40% of rats with cirrhosis. Compared with the group without BT, these animals exhibited diminished intestinal Paneth cell α-cryptdin 5 and 7 expression. In contrast, PVL was associated with BT in all animals but did not affect antimicrobial peptides. The decrease in Paneth cell antimicrobials was most pronounced in the ileum and the coecum. Other antimicrobials showed no changes or even an induction in the case of BT at different sites. Antimicrobial activity toward different commensal strains was reduced, especially in the distal ileum and the cecum in experimental cirrhosis with BT (excluding PVL).
CONCLUSION: Compromised Paneth cell antimicrobial host defense seems to predispose to BT in experimental cirrhosis. Understanding this liver-gut axis including the underlying mechanisms could help us to find new treatment avenues.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22095436     DOI: 10.1002/hep.24789

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  69 in total

Review 1.  Bacterial infections in end-stage liver disease: current challenges and future directions.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Florence Wong; K Rajender Reddy; Patrick S Kamath
Journal:  Gut       Date:  2012-06-03       Impact factor: 23.059

2.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 3.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

Review 4.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

5.  Compromise of α-Defensin Function in Liver Cirrhosis Facilitates the Toxic Relationship Between Gut Permeability and Endotoxemia.

Authors:  Kanakaraju Kaliannan
Journal:  Dig Dis Sci       Date:  2018-10       Impact factor: 3.199

6.  Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; K Rajender Reddy; Florence Wong; Jody C Olson; Ram M Subramanian; Geri Brown; Nicole A Noble; Leroy R Thacker; Patrick S Kamath
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

Review 7.  The role of microbiota in hepatic encephalopathy.

Authors:  Jasmohan S Bajaj
Journal:  Gut Microbes       Date:  2014-04-01

Review 8.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Linking intestinal homeostasis and liver disease.

Authors:  Bernd Schnabl
Journal:  Curr Opin Gastroenterol       Date:  2013-05       Impact factor: 3.287

10.  Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.

Authors:  Yun-Xia Chen; Li-Na Lai; Hui-Ying Zhang; Yang-Hui Bi; Li Meng; Xu-Jiong Li; Xiao-Xia Tian; Li-Min Wang; Yi-Min Fan; Zhong-Fu Zhao; De-Wu Han; Cheng Ji
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.